At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 15,000 target
Drug / intervention
Immune checkpoint inhibitordrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
In Brief
An observational study evaluating Immune checkpoint inhibitor for Non Small Cell Lung Cancer. Currently recruiting, targeting 15,000 participants across 1 site.
Detailed Summary
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
N/ARecruiting
2022202320242025202620272028
First PostedSep 2021
Enrollment StartOct 2021
TodayJul 2026
Primary CompletionSep 2026
Study CompletionMar 2028
First PostedSep 28, 2021
Enrollment StartOct 3, 2021
Primary CompletionSep 15, 2026
Study CompletionMar 1, 2028
TodayJul 1, 2026
Enrollment to primary: 5.0 yearsPosted 4.8 years agoPrimary completion in 2 months
Interventions
Immune checkpoint inhibitordrug
Chemotherapy follow the guild line.